Optus Pharmaceutical Co Ltd
KOSDAQ:131030
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Optus Pharmaceutical Co Ltd
Operating Income
Optus Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Optus Pharmaceutical Co Ltd
KOSDAQ:131030
|
Operating Income
₩8.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-1%
|
|
|
Suheung Co Ltd
KRX:008490
|
Operating Income
₩50.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
4%
|
|
|
SD Biosensor Inc
KRX:137310
|
Operating Income
-₩54.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Operating Income
₩23.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Operating Income
-₩104.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-33%
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Operating Income
₩57B
|
CAGR 3-Years
37%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Optus Pharmaceutical Co Ltd
Glance View
OPTUS Pharmaceutical Co., Ltd. engages in the manufacture and sale of ophthalmic products. The company is headquartered in Cheongju, Chungcheongbuk-Do and currently employs 171 full-time employees. The company went IPO on 2010-12-03. The firm is primarily engaged in the manufacture and sale of eye drops and ophthalmic preparations such as dry eye treatment agents, conjunctivitis treatment agents, anti-inflammatory medication agents, glaucoma treatment agents and others.
See Also
What is Optus Pharmaceutical Co Ltd's Operating Income?
Operating Income
8.9B
KRW
Based on the financial report for Dec 31, 2025, Optus Pharmaceutical Co Ltd's Operating Income amounts to 8.9B KRW.
What is Optus Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-1%
Over the last year, the Operating Income growth was 3%. The average annual Operating Income growth rates for Optus Pharmaceutical Co Ltd have been 19% over the past three years , -11% over the past five years , and -1% over the past ten years .
